Table 1 Baseline demographic and clinical characteristics of patients in the protamine and non-protamine groups
All (n = 160) | Protamine group (n = 92) | Non-protamine group (n = 68) | p value | |
|---|---|---|---|---|
Age, years | 68.6 ± 10.4 | 68.1 ± 10.9 | 69.2 ± 9.7 | 0.518 |
Male sex | 108 (67.5) | 61 (66.3) | 47 (69.1) | 0.707 |
Body mass index, kg/m2 | 24.2 ± 3.4 | 24.4 ± 3.2 | 23.9 ± 3.5 | 0.329 |
Smoking | 43 (26.9) | 27 (29.3) | 16 (23.5) | 0.412 |
Cardiac or coexisting conditions | ||||
Hypertension | 103 (64.4) | 57 (62.0) | 46 (67.6) | 0.457 |
Diabetes mellitus | 76 (47.5) | 38 (41.3) | 38 (55.9) | 0.068 |
Chronic kidney disease | 31 (19.4) | 15 (16.3) | 16 (23.5) | 0.253 |
Previous myocardial infarction | 18 (11.3) | 12 (13.0) | 6 (8.8) | 0.404 |
Previous PCI | 32 (20.0) | 20 (21.7) | 12 (17.6) | 0.522 |
Previous CABG | 7 (4.4) | 5 (5.4) | 2 (2.9) | 0.700 |
Dyslipidemia | 79 (49.4) | 44 (47.8) | 35 (51.5) | 0.649 |
Hemoglobin, g/dL | 12.1 ± 2.4 | 12.0 ± 2.5 | 12.1 ± 2.2 | 0.783 |
Platelet, × 103 cells/mL | 219.1 ± 64.8 | 219.9 ± 61.3 | 218.0 ± 69.7 | 0.855 |
Left ventricular ejection fraction, % | 54.3 ± 12.5 | 54.6 ± 12.4 | 53.9 ± 12.7 | 0.721 |
Clinical presentation | 0.357 | |||
Stable CAD | 11 (6.9) | 8 (8.7) | 3 (4.4) | |
ACS* | 149 (93.1) | 84 (91.3) | 65 (95.6) | |
Dual antiplatelet therapy | 0.069 | |||
Aspirin and clopidogrel | 97 (60.6) | 58 (63.0) | 39 (57.4) | |
Aspirin and ticagrelor | 46 (28.8) | 21 (22.8) | 25 (36.8) | |
Aspirin and prasugrel | 17 (10.6) | 13 (14.1) | 4 (5.9) |